Answer
Brigatinib (Alunbrig) should not be used during pregnancy unless the mother's clinical condition requires treatment; it may harm the foetus, animal studies show reproductive toxicity, no clinical pregnancy data exist, and patients treated during pregnancy or becoming pregnant during treatment should be informed of the potential foetal hazard.
Sources for this answer
- Alunbrig 30 mg film-coated tabletsTakeda UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 11Document updated
Sources checked